Management of hyperuricemia in gout: Focus on febuxostat

Clinical Interventions in Aging

Volumn 5, Issue 1, 2010, Pages 7-18

  Reinders, Mattheus K ^a   Jansen, Tim L Th A ^b  

^a Sittard Geleen Heerlen   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

Aging; Febuxostat; Gout; Hyperuricemia; Pharmacotherapy; Xanthine oxidase

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; ASCORBIC ACID; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; FEBUXOSTAT; FENOFIBRATE; LOSARTAN; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROBENECID; RASBURICASE; SALICYLIC ACID DERIVATIVE;

CLINICAL TRIAL; COOLING; CREATININE CLEARANCE; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG USE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GLOMERULUS FILTRATION RATE; GOUT; HOMEOSTASIS; HUMAN; HYPERURICEMIA; KIDNEY CLEARANCE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIVER FUNCTION; NAUSEA; PATHOGENESIS; PHARMACODYNAMICS; POLARIZATION MICROSCOPY; POSTMARKETING SURVEILLANCE; PRIMARY PREVENTION; RADIODIAGNOSIS; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; URIC ACID BLOOD LEVEL; URIC ACID NEPHROPATHY; VOMITING;

EID: 77951247969     PISSN: 11769092     EISSN: 11781998     Source Type: Journal    
DOI: 10.2147/cia.s5476     Document Type: Review

References (76)

1. Singh H, Torralba KD. Therapeutic challenges in the management of gout in the elderly. Geriatrics. 2008;63(7):13-18, 20.
2. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis Res Ther. 2006;8 (Suppl 1):S2.
3. Pascual E, Sivera F. Why is gout so poorly managed? Ann Rheum Dis. 2007;66(10):1269-1270.
4. Zhang W, Doherty M, Pascual E, et al; for EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout - Part I Diagnosis: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1301-1311.
5. Zhang W, Doherty M, Bardin T, et al; for EULAR Standing Committee for International Clinical Studies Including Therapeutic. EULAR evidence based recommendations for gout - Part II Management: Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2006;65(10):1312-1324.
6. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol. 29(11): 2403-2406.
7. Wallace K, Riedel A, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol. 2004;31(8):1582-1587.
8. Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging. 1998;13(3):229-243.
9. Ene-Stroescu D, Gorbien MJ. Gouty arthritis. A primer on late-onset gout. Geriatrics. 2005;60(7):24-31.
10. Hoskison KT, Wortmann RL. Management of gout in older adults: barriers to optimal control. Drugs Aging. 2007;24(1):21-36.
11. De Leonardis F, Govoni M, Colina M, Bruschi M, Trotta F. Elderly-onset gout: a review. Rheumatol Int. 2007;28(1):1-6.
12. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med. 2005;143(7):499-516.
13. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature. 2002;417(6887):447-452.
14. Kolz M, Johnson T, Sanna S, et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 2009;5(6): e1000504.
15. Spieker LE, Ruschitzka FT, Lüscher TF, Noll G. The management of hyperuricemia and gout in patients with heart failure. Eur J Heart Fail. 2002;4(4):403-410.
16. Bagatin J, Sardelic S, Pivac N, et al. Comparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertension. Int J Clin Pharmacol Res. 1998;18:73-78.
17. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol. 1997;50:953-959.
18. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995;49:121-142.
19. Caspi D, Lubart E, Graff E, Habot B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum. 2000;43(1):103-108.
20. Dieppe PA. Investigation and management of gout in the young and the elderly. Ann Rheum Dis. 1991;50(4):263-266.
21. Pascual E, Tovar J, Ruiz MT. The ordinary light microscope: an appropriate tool for provisional detection and identification of crystals in synovial fluid. Ann Rheum Dis. 1989;48(12):983-985.
22. Kanellis J, Kang D-H, Feig DI, et al. Asymptomatic hyperuricemia. In: Wortmann RL, Becker MA, Ryan LM, editors. Crystal-Induced Artrhopathies: Gout, Pseudogout and Apatite-Associated Syndromes. New York: Taylor and Francis Group; 2006:84-85.
23. Schlesinger N, Detry MA, Holland BK, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol. 2004;29(2):331-334.
24. Janssens HJ, Janssen M, van de Lisdonk EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet. 2008;371(9627):1854-1860.
25. Rubin BR, Burton R, Navarra S, Smugar SS, Tershakovec AM. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial. Arthritis Rheum. 2004;50(7):598-606.
26. Schumacher HR Jr, Boice JA, Daikh DI, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis. BMJ. 2002;324(7352):1488-1492.
27. Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol. 1999;34(1):60-63.
28. Ka T, Inokuchi T, Tsutsumi Z, Takahashi S, Moriwaki Y, Yamamoto T. Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases. Int J Clin Pharmacol Ther. 2006;44(1):22-26.
29. Gao X, Curhan G, Forman JP, Ascherio A, Choi HK. Vitamin C intake and serum uric acid concentration in men. J Rheumatol. 2008; 35(9):1853-1858.
30. Choi HK, Gao X, Curhan G. Vitamin C intake and the risk of gout in men: a prospective study. Arch Intern Med. 2009;169(5):502-507.
31. Levinson W, Cohen MS, Brady D, et al. To change or not to change: "Sounds like you have a dilemma". Ann Intern Med. 2001;135(5): 386-391.
32. Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G. Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med. 2004;350(11):1093-1103.
33. Ferraz MB, O'Brien B. A cost effectiveness analysis of urate lowering drugs in nontophaceous recurrent gouty arthritis. J Rheumatol. 1995; 22(5):908-914.
34. Pérez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum. 2002;47(4): 356-360.
35. Sarawate CA, Patel PA, Schumacher HR, et al. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol. 2006; 12(2):61-65.
36. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum. 2004;51(3):321-325.
37. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol. 1998;431:13-18.
38. Jordan KM, Cameron JS, Snaith M, et al; for British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British society for Rheumatology and British Health Professionals in Rheumatology guideling for the management of gout. Rheumatology (Oxford). 2008;46(8):1372-1374.
39. Sutaria S, Katbamna R, Underwood M. Effectiveness of interventions for the treatment of acute and prevention of recurrent gout - a systematic review. Rheumatology (Oxford). 2006;45(11):1422-1431.
40. Pérez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, García-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis. 1998;57(9): 545-549.
41. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
42. Reinders MK, van Roon EN, Houtman PM, Brouwers JR, Jansen TL. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients. Clin Rheumatol. 2007;26(5):1459-1465.
43. Reinders MK, Van Roon EN, Jansen TLThA, et al. Efficacy and tolerability of urate lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol. Ann Rheum Dis. 2009;68(1):51-56.
44. Reinders MK, Haagsma C, Jansen TLTA, et al. A randomized controlled trial with dose escalation on the efficacy and tolerability of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in gout patients. Ann Rheum Dis. 2009;68(6):892-897.
45. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol. 2006;33(8): 1646-1650.
46. Chung Y, Stocker SL, Graham GG, Day RO. Optimizing therapy with allopurinol: factors limiting hypouricemic efficacy. Am J Med Sci. 2008;335(3):219-226.
47. Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol. 2008;14(1):6-11.
48. Borstad GC, Bryant LR, Abel MP, Scroggie DA, Harris MD, Alloway JA. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol. 2004;31(12): 2429-2432.
49. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Current Opin Rheumatol. 2005;17(3):319-324.
50. Arellano F, Sacristán JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother. 1993;27(3):337-343.
51. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76(1):47-56.
52. CHMP 2008. Committee for medicinal products for human use summary of positive opinion for adenuric. 21 February 2008. URL: http://www.emea.europa.eu/pdfs/human/opinion/Adenuric_8075108en.pdf.
53. CDER 2009. Center for Drug Evaluation and Research. URL: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm149534.htm.
54. Jansen TL, Reinders MK, Van Roon EN, Brouwers JRBJ. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence?" Clin Exp Rheumatol. 2004; 22(5):651.
55. Lee MH, Graham GG, Williams KM, Day RO. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf. 2008;31(8): 643-665.
56. Moolenburgh JD, Reinders MK, Jansen TL. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol. 2006;25(5):749-752.
57. Vogt B. Urate oxidase (rasburicase) for treatment of severe tophaceous gout. Nephrol Dial Transplant. 2005;20(2):431-433.
58. Becker MA, Kisicki J, Khosravan R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids. 2004;23(8-9):1111-1116.
59. Khosravan R, Kukulka MJ, Wu JT, Joseph-Ridge N, Vernillet L. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2008;48(9):1014-1024.
60. Khosravan R, Grabowski B, Wu JT, Joseph-Ridge N, Vernillet L. Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. Br J Clin Pharmacol. 2008;65(3): 355-363.
61. Schumacher HR Jr. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs. 2005;14(7):893-903.
62. Hair PI, McCormack PL, Keating GM. Febuxostat. Drugs. 2008; 68(13):1865-1874.
63. Bruce SP. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout. Ann Pharmacother. 2006;40(12): 2187-2194.
64. Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am J Ther. 2005;12(1):22-34.
65. Hoshide S, Takahashi Y, Ishikawa T, et al. PK/PD and safety of a single dose of TMX-67 (febuxostat) in subjects with mild and moderate renal impairment. Nucleosides Nucleotides Nucleic Acids. 2004; 23(8-9):1117-1118.
66. Khosravan R, Grabowski BA, Mayer MD, Wu JT, Joseph-Ridge N, Vernillet L. The effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase. J Clin Pharmacol. 2006;46(1):88-102.
67. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005;52(3):916-923.
68. Schumacher HR, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009;48(2):188-194.
69. Becker MA, Schumacher HR Jr, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005;353(23):2450-2461.
70. Moreland LW. Febuxostat treatment for hyperuricemia and gout? N Engl J Med. 2005;353(23):2505-2507.
71. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med. 1966;64(2):229-258.
72. Schumacher HR Jr, Becker MA, Wortmann RL, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum. 2008;59(11):1540-1548.
73. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009;36(6):1273-1282.
74. Becker M, Schumacher HR Jr, Espinoza L, et al. A phase 3 randomized, controlled, multicenter, double-blind trial comparing efficacy and safety of daily febuxostat and allopurinol in subjects with gout. Presented at: the Meeting of the American College of Rheumatology; October 24-29, 2008; San Francisco, California. URL: http://acr.confex.com/acr/2008/webprogram/Paper3414.html.
75. Gaffo AL, Saag KG. Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout. Core Evidence. 2009;4:25-36.
76. European Medicines Agency (EMEA). Summary of product characteristics. 19/05/2009 Adenuric-H-C-777-T-13. URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/adenuric/emea-combined-h77 7en.pdf.